Product Description
A tVNS instrument consisting of two titan electrodes mounted on a gel frame and connected to a wired neurostimulating device (CM02, Cerbomed, Erlangen, Germany) was used.
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Guangdong Provincial Hospital of Chinese Medicine
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR1800019905 | N/A |
Recruiting |
Psoriasis |
2019-12-31 |
|
| ChiCTR-IOR-15006768 | N/A |
Recruiting |
Psoriasis |
2017-06-30 |
|
| ChiCTR-IOR-17011075 | N/A |
Not yet recruiting |
Psoriasis |
2017-12-30 |
|
| ChiCTR-IOR-17012238 | N/A |
Recruiting |
Psoriasis |
2020-04-01 |
|
| cMPsE01 | N/A |
Completed |
Epilepsy |
2010-09-01 |